158 related articles for article (PubMed ID: 6105677)
21. Estrogen in experimental tardive dyskinesia.
Gordon JH; Borison RL; Diamond BI
Neurology; 1980 May; 30(5):551-4. PubMed ID: 7189262
[TBL] [Abstract][Full Text] [Related]
22. Central action of melanostatin (MIF-1) in mice.
Brus R; Szkilnik R; Stanosek B; Makowska B; Piguła J
Acta Physiol Pol; 1984; 35(5-6):447-53. PubMed ID: 6152791
[TBL] [Abstract][Full Text] [Related]
23. Differential liabilities of haloperidol and thioridazine for inducing apomorphine hypersensitivity.
De Veaugh-Geiss J; Devanand DP; Carey RJ
Biol Psychiatry; 1982 Nov; 17(11):1289-301. PubMed ID: 6891268
[TBL] [Abstract][Full Text] [Related]
24. Possible aminergic mediation of MSH release and of the CNS effects of MSH and MIF-I.
Kastin AJ; Schally AV; Kostrzewa RM
Fed Proc; 1980 Sep; 39(11):2931-6. PubMed ID: 6105977
[TBL] [Abstract][Full Text] [Related]
25. Enhanced striatal 3H-spiroperidol binding induced by chronic haloperidol treatment inhibited by peptides administered during the withdrawal phase.
Bhargava HN
Life Sci; 1984 Feb; 34(9):873-9. PubMed ID: 6142397
[TBL] [Abstract][Full Text] [Related]
26. Pro-Leu-Gly-NH2 and pareptide inhibit development of tolerance to haloperidol catalepsy in the mouse.
Mycroft FJ; Wei ET
Peptides; 1984; 5(5):883-7. PubMed ID: 6150468
[TBL] [Abstract][Full Text] [Related]
27. Melanocyte-stimulating hormone release-inhibiting factor (MIF): lack of dopaminergic and anticholinergic activity.
Carolei A; Margotta V; Palladini G
Neuroendocrinology; 1977; 23(3):129-32. PubMed ID: 19714
[TBL] [Abstract][Full Text] [Related]
28. Attenuation of morphine analgesia by alpha-MSH, MIF-I, melatonin and naloxone in the rat.
Datta PC; Sandman CA; Hoehler FK
Peptides; 1982; 3(3):433-7. PubMed ID: 6126866
[TBL] [Abstract][Full Text] [Related]
29. Acute administration of MIF-1 or Tyr-MIF-1 inhibits haloperidol-induced catalepsy in rats.
Hara C; Kastin AJ
Pharmacol Biochem Behav; 1986 Jun; 24(6):1785-7. PubMed ID: 2874569
[TBL] [Abstract][Full Text] [Related]
30. Investigations on alpha-MSH and MIF-1 effects on cyclic AMP levels in rat brain.
Christensen CW; Harston CT; Kastin AJ; Kostrzewa RM; Spirtes MA
Pharmacol Biochem Behav; 1976; 5(Suppl 1):117-20. PubMed ID: 13410
[TBL] [Abstract][Full Text] [Related]
31. Hypothalamic alpha-melanocyte-stimulating hormone (alpha-MSH) is not under dopaminergic control.
Delbende C; Jégou S; Tranchand-Bunel D; Pelletier G; Vaudry H
Brain Res; 1987 Oct; 423(1-2):203-12. PubMed ID: 2960424
[TBL] [Abstract][Full Text] [Related]
32. alpha-MSH and Pro-Leu-Gly-NH2 (PLG; MIF-1): influence on dopamine (DA) uptake in crude synaptosomal preparations from rat mediobasal hypothalamus (MBH) and caudate putamen (CP).
Torre E; Celis ME; Chiocchio SR
Peptides; 1984; 5(4):669-74. PubMed ID: 6149522
[TBL] [Abstract][Full Text] [Related]
33. The effects of MIF-I, beta-endorphin and alpha-MSH on d-amphetamine induced paradoxical behavioral thermoregulation: possible involvement of the dopaminergic system.
Yehuda S; Sheleff P
Peptides; 1985; 6(2):189-92. PubMed ID: 2863810
[TBL] [Abstract][Full Text] [Related]
34. Inhibition by L-prolyl-L-leucyl-glycinamide (PLG) of alpha-melanocyte stimulating hormone release from hypothalamic slices.
Scimonelli T; Celis ME
Peptides; 1982; 3(6):885-9. PubMed ID: 6132363
[TBL] [Abstract][Full Text] [Related]
35. Selective effects of alpha-MSH and MIF-1 on the blood-brain barrier.
Sankar R; Domer FR; Kastin AJ
Peptides; 1981; 2(3):345-7. PubMed ID: 6117842
[TBL] [Abstract][Full Text] [Related]
36. Melanocyte-stimulating-hormone release-inhibiting factor-I and tardive dyskinesia.
Ehrensing RH; Kastin AJ; Larsons PF; Bishop GA
Dis Nerv Syst; 1977 Apr; 38(4):303-7. PubMed ID: 14814
[No Abstract] [Full Text] [Related]
37. Effects of the tripeptides TRH, MIF and MAF on the cerebral dopaminergic system.
Klusha B; Georgiev V; Petkov V; Markovska V
Acta Physiol Pharmacol Bulg; 1983; 9(2):14-9. PubMed ID: 6140814
[TBL] [Abstract][Full Text] [Related]
38. Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: A model of human tardive dyskinesia.
Sharma S; Paladino P; Gabriele J; Saeedi H; Henry P; Chang M; Mishra RK; Johnson RL
Peptides; 2003 Feb; 24(2):313-9. PubMed ID: 12668218
[TBL] [Abstract][Full Text] [Related]
39. Melanocyte-stimulating hormone and persistent tardive dyskinesia: a hypothesis.
Sandyk R
Int J Neurosci; 1990 Mar; 51(1-2):45-52. PubMed ID: 1979965
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the regulation of rotational behavior by hypothalamic oligopeptides.
Cohn ML; Cohn M
Psychoneuroendocrinology; 1977; 2(2):197-202. PubMed ID: 23561
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
